ProfileGDS5678 / 1454102_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 6% 6% 6% 6% 7% 6% 6% 6% 6% 6% 6% 6% 11% 6% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.145246
GSM967853U87-EV human glioblastoma xenograft - Control 22.130166
GSM967854U87-EV human glioblastoma xenograft - Control 32.133366
GSM967855U87-EV human glioblastoma xenograft - Control 42.082856
GSM967856U87-EV human glioblastoma xenograft - Control 52.093187
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.17196
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.144416
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.114266
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.103516
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.121666
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.116546
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.106396
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.2737611
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.121446